Cost-effective market access strategy for medical technologies in Europe
A holistic approach to reimbursement strategies trusted by global market leaders and SMEs
Recent news and posts
The new version of NABM nomenclature released in France
On September 6, 2024, the new version of the Nomenclature of Medical Biology Acts (NABM 92), effective from September 10, 2024, was released.
One new code was introduced: 4513 "Test for determining the status of homologous recombination pathway deficiency (HRD) in ovarian cancer for targeted therapy [Companion test]".
Other changes include modification of the coefficient B rating for a number of codes and deletion of Article 4 "Minimum quotations" from the general provisions section of the NABM and 18 codes of this section.
See the details in French here (NABM) and here (Order on NABM changes).
This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.